Navigation Links
Antibacterial Therapies Drug Development Pipeline Review 2017: 1400 Products in Active Development - Which Companies are the Most Active? - Research and Markets
Date:4/10/2017

DUBLIN, Apr. 10, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Antibacterial Therapies Drug Development Pipeline Review, 2017" report to their offering.

The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage.

This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.

There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.

Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body's immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.

Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.

Scope

- Which companies are the most active within the pipeline for antibacterial drugs?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Key Topics Covered:

1. Introduction

2. Research Report Coverage

3. Tuberculosis Overview

4. Therapeutics Development

5. Therapeutics under Development by Companies

6. Therapeutics under Investigation by Universities/Institutes

7. Pipeline Products Glance

8. Products under Development by Companies

9. Products under Investigation by Universities/Institutes

10. Companies Involved in Therapeutics Development

11. Therapeutics Assessment

12. Dormant Projects

13. Discontinued Products

14. Product Development Milestones

15. Appendix

Companies Mentioned

- Abera Bioscience AB,
- Akthelia Pharmaceuticals Limited,
- Alvogen Korea Co., Ltd.,
- Anacor Pharmaceuticals, Inc.,
- Archivel Farma S.L.,
- AstraZeneca Plc,
- Beech Tree Labs, Inc.,
- BioDiem Ltd,
- BioLingus AG,
- Biomar Microbial Technologies,
- Bioversys AG,
- Celgene Corporation,
- Dafra Pharma International Ltd.,
- Daiichi Sankyo Company, Limited,
- Demuris Limited,
- Eisai Co., Ltd.,
- Eli Lilly and Company,
- GangaGen Inc.,
- GlaxoSmithKline Plc,
- Globeimmune, Inc.,
- Hager Biosciences, LLC,
- Hsiri Therapeutics LLC,
- Imaxio SA,
- Immunitor, Inc.,
- ImmunoBiology Limited,
- Lipotek Pty Ltd.,
- Matinas BioPharma Holdings, Inc. ,
- Microbion Corporation,
- Microbiotix, Inc.,
- NEARMEDIC PLUS, Ltd,
- Novartis AG,
- NovoBiotic Pharmaceuticals, LLC,
- Otsuka Holdings Co., Ltd.,
- QureTech Bio AB,
- Rodos BioTarget GmbH

For more information about this report visit http://www.researchandmarkets.com/research/8gfsmj/antibacterial

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/antibacterial-therapies-drug-development-pipeline-review-2017-1400-products-in-active-development---which-companies-are-the-most-active---research-and-markets-300437154.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Antibacterial Drugs Market to 2022: Antibacterial Drug Market will Hit $35.6 Billion by 2022, as Efforts Increase to Tackle Antimicrobial Resistance - Research and Markets
2. Antibacterial Drug Resistance: Market Landscape, Challenges and Upcoming
3. Antibacterial Drugs: World Industry and Market Prospects 2016-2026
4. Growth in Global Antibacterial Drugs Market Limited to 1.30% CAGR Owing to Patent Expiries: Transparency Market Research
5. Global Antibacterial Drugs Market 2015-2019 - Key Vendors are Allergan, GlaxoSmithKline, Merck, Novartis, Pfizer & Teva Pharmaceuticals
6. Antibacterial Drugs Market 2015-2019 - Trends, Analysis, Key Players and Forecast
7. Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDA for Novel Antibacterial Product
8. Antibacterial Drugs Market Expected to Reach USD 38.9 Billion Globally in 2023, at CAGR of 1.3% From 2015 to 2023: Transparency Market Research
9. Development and Commercialization of Antibacterial Drugs to Speed Up
10. Antibacterial Drugs Market (By Class and Pipeline Analysis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
11. Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Markets to 2023: Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market - Research and Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)...  According to the Centers for Disease Control and Prevention (CDC), ... Urgent Care is helping communities across Massachusetts , ... offering no-cost* flu shots through the end of the month. ... regulations. ... a flu shot is by the end of October, according to the ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
(Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains ... possible to save lost souls in the Philippines. “The Journey: From the Mountains to ... dedicated teacher of the Bible. She has taught all ages and currently teaches a ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
Breaking Medicine News(10 mins):